Human Gene LMNA (ENST00000368300.9_4) from GENCODE V47lift37
  Description: lamin A/C, transcript variant 1 (from RefSeq NM_170707.4)
Gencode Transcript: ENST00000368300.9_4
Gencode Gene: ENSG00000160789.25_17
Transcript (Including UTRs)
   Position: hg19 chr1:156,084,502-156,109,872 Size: 25,371 Total Exon Count: 12 Strand: +
Coding Region
   Position: hg19 chr1:156,084,710-156,108,897 Size: 24,188 Coding Exon Count: 12 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesGeneReviewsModel Information
Methods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr1:156,084,502-156,109,872)mRNA (may differ from genome)Protein (664 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: LMNA_HUMAN
DESCRIPTION: RecName: Full=Prelamin-A/C; Contains: RecName: Full=Lamin-A/C; AltName: Full=70 kDa lamin; AltName: Full=Renal carcinoma antigen NY-REN-32; Flags: Precursor;
FUNCTION: Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Plays an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics.
FUNCTION: Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.
SUBUNIT: Homodimer of lamin A and lamin C. Interacts with lamin- associated polypeptides IA, IB and TMPO-alpha, RB1 and with emerin. Interacts with SREBF1, SREBF2, SUN2 and TMEM43 (By similarity). Proteolytically processed isoform A interacts with NARF. Interacts with SUN1. Prelamin-A/C interacts with EMD. Interacts with MLIP; may regulate MLIP localization to the nucleus envelope. Interacts with DMPK; may regulate nuclear envelope stability.
INTERACTION: P18054:ALOX12; NbExp=4; IntAct=EBI-351935, EBI-1633210;
SUBCELLULAR LOCATION: Nucleus. Nucleus envelope. Note=Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.
TISSUE SPECIFICITY: In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle cells (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
PTM: Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
PTM: Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin- A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage.
PTM: Sumoylation is necessary for the localization to the nuclear envelope.
PTM: Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
DISEASE: Defects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 2, autosomal dominant (EDMD2) [MIM:181350]. A degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
DISEASE: Defects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 3, autosomal recessive (EDMD3) [MIM:181350].
DISEASE: Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
DISEASE: Defects in LMNA are the cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. A disorder characterized by the loss of subcutaneous adipose tissue in the lower parts of the body (limbs, buttocks, trunk). It is accompanied by an accumulation of adipose tissue in the face and neck causing a double chin, fat neck, or cushingoid appearance. Adipose tissue may also accumulate in the axillae, back, labia majora, and intraabdominal region. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus after age 20 years, hypertriglyceridemia, and low levels of high density lipoprotein cholesterol.
DISEASE: Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.
DISEASE: Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.
DISEASE: Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging. Note=HGPS is caused by the toxic accumulation of a mutant form of lamin-A/C. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. Progerin lacks the conserved ZMPSTE24/FACE1 cleavage site and therefore remains permanently farnesylated. Thus, although it can enter the nucleus and associate with the nuclear envelope, it cannot incorporate normally into the nuclear lamina.
DISEASE: Defects in LMNA are the cause of cardiomyopathy dilated with hypergonadotropic hypogonadism (CMDHH) [MIM:212112]. A disorder characterized by the association of genital anomalies, hypergonadotropic hypogonadism and dilated cardiomyopathy. Patients can present other variable clinical manifestations including mental retardation, skeletal anomalies, scleroderma-like skin, graying and thinning of hair, osteoporosis. Dilated cardiomyopathy is characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia.
DISEASE: Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, progeroide appearance, partial alopecia, soft tissue calcinosis, joint contractures, and partial lipodystrophy with loss of subcutaneous fat from the extremities. Adipose tissue in the face, neck and trunk is normal or increased.
DISEASE: Defects in LMNA are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also known as restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
DISEASE: Defects in LMNA are the cause of heart-hand syndrome Slovenian type (HHS-Slovenian) [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.
DISEASE: Defects in LMNA are the cause of muscular dystrophy congenital LMNA-related (MDCL) [MIM:613205]. It is a form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.
MISCELLANEOUS: There are three types of lamins in human cells: A, B, and C.
MISCELLANEOUS: The structural integrity of the lamina is strictly controlled by the cell cycle, as seen by the disintegration and formation of the nuclear envelope in prophase and telophase, respectively.
SIMILARITY: Belongs to the intermediate filament family.
SEQUENCE CAUTION: Sequence=CAA27173.1; Type=Frameshift; Positions=582;
WEB RESOURCE: Name=Human Intermediate Filament Mutation Database; URL="http://www.interfil.org";
WEB RESOURCE: Name=GeneReviews; URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/LMNA";

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: LMNA
Diseases sorted by gene-association score: hutchinson-gilford progeria* (1726), mandibuloacral dysplasia* (1712), muscular dystrophy, limb-girdle, type 1b* (1679), charcot-marie-tooth disease, type 2b1* (1666), lipodystrophy, familial partial, type 2* (1650), malouf syndrome* (1650), muscular dystrophy, congenital* (1586), emery-dreifuss muscular dystrophy 2, ad* (1572), emery-dreifuss muscular dystrophy 3, ar* (1550), heart-hand syndrome, slovenian type* (1369), cardiomyopathy, dilated, 1a* (1248), restrictive dermopathy, lethal* (895), lmna-related dilated cardiomyopathy* (500), limb-girdle muscular dystrophy* (485), cardiomyopathy* (480), dilated cardiomyopathy* (470), atypical werner syndrome* (468), congenital muscular dystrophy due to lmna mutation* (417), autosomal semi-dominant severe lipodystrophic laminopathy* (350), lmna-related cardiocutaneous progeria syndrome* (350), progeria-associated arthropathy* (350), muscular dystrophy* (341), epidermolysis bullosa simplex with muscular dystrophy* (283), charcot-marie-tooth disease, axonal, type 2s* (233), lmna-related muscle diseases* (200), charcot-marie-tooth disease* (191), scn5a-associated dilated cardiomyopathy* (179), scn5a-related dilated cardiomyopathy* (179), emery-dreifuss muscular dystrophy* (177), cardiomyopathy, dilated, 1e* (163), myh7-related dilated cardiomyopathy* (163), atrial standstill, digenic* (151), familial isolated arrhythmogenic ventricular dysplasia, right dominant form* (143), familial isolated arrhythmogenic ventricular dysplasia, biventricular form* (143), familial isolated arrhythmogenic ventricular dysplasia, left dominant form* (143), roussy-levy syndrome* (133), charcot-marie-tooth disease, type 2e* (128), dilated cardiomyopathy with quadriceps myopathy* (100), lethal restrictive dermopathy, lmna-related* (100), progeroid laminopathies* (100), lmna-related emery-dreifuss muscular dystrophy, autosomal* (100), familial partial lipodystrophy (51), lipodystrophy (41), autosomal dominant limb-girdle muscular dystrophy (26), lipodystrophy, familial partial, type 1* (25), atrioventricular block (18), congenital generalized lipodystrophy (17), werner syndrome (15), ovarian cystadenoma (15), pelger-huet anomaly (14), calcinosis (14), left ventricular noncompaction* (13), reynolds syndrome (12), emerinopathy (12), hajdu-cheney syndrome (12), tooth disease (12), cardiomyopathy, dilated, 1h (11), ulnar nerve lesion (11), median neuropathy (11), arrhythmogenic right ventricular cardiomyopathy (9), acanthosis nigricans (9), proximal myopathy and ophthalmoplegia (8), glucose intolerance (8), muscular dystrophy, congenital merosin-deficient (7), axonal neuropathy (7), sick sinus syndrome (7), xeroderma pigmentosum, group a (6), leukodystrophy, adult-onset, autosomal dominant (6), second-degree atrioventricular block (6), hypertriglyceridemia (6), proximal spinal muscular atrophy (6), congenital fiber-type disproportion (6), hereditary neuropathies (6), intrinsic cardiomyopathy (5), myopathy (5), ullrich congenital muscular dystrophy 1 (5), ventricular tachycardia, catecholaminergic polymorphic, 1 (4), bethlem myopathy 1 (4), hallermann-streiff syndrome (4), muscular dystrophy, limb-girdle, type 2a (4), muscular dystrophy-dystroglycanopathy , type b, 5 (4), alopecia (3), heart disease (3), skin disease (2), autosomal genetic disease (1), muscle tissue disease (1), fanconi anemia, complementation group a (1), diabetes mellitus, noninsulin-dependent (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 124.86 RPKM in Skin - Not Sun Exposed (Suprapubic)
Total median expression: 2358.63 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -66.10208-0.318 Picture PostScript Text
3' UTR -393.40975-0.403 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR016044 - F
IPR001664 - IF
IPR018039 - Intermediate_filament_CS
IPR001322 - Lamin_tail_dom

Pfam Domains:
PF00038 - Intermediate filament protein
PF00932 - Lamin Tail Domain

SCOP Domains:
74853 - Lamin A/C globular tail domain
64593 - Intermediate filament protein, coiled coil region
90257 - Myosin rod fragments

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1IFR - X-ray MuPIT 1IVT - NMR MuPIT 1X8Y - X-ray MuPIT 2XV5 - X-ray MuPIT 3GEF - X-ray MuPIT 3V4Q - X-ray MuPIT 3V4W - X-ray MuPIT 3V5B - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P02545
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGD    
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0005198 structural molecule activity
GO:0005515 protein binding
GO:0042802 identical protein binding

Biological Process:
GO:0006606 protein import into nucleus
GO:0006997 nucleus organization
GO:0006998 nuclear envelope organization
GO:0007084 mitotic nuclear envelope reassembly
GO:0007517 muscle organ development
GO:0008285 negative regulation of cell proliferation
GO:0010628 positive regulation of gene expression
GO:0030334 regulation of cell migration
GO:0030951 establishment or maintenance of microtubule cytoskeleton polarity
GO:0032204 regulation of telomere maintenance
GO:0034504 protein localization to nucleus
GO:0034613 cellular protein localization
GO:0036498 IRE1-mediated unfolded protein response
GO:0055015 ventricular cardiac muscle cell development
GO:0071456 cellular response to hypoxia
GO:0072201 negative regulation of mesenchymal cell proliferation
GO:0090201 negative regulation of release of cytochrome c from mitochondria
GO:0090343 positive regulation of cell aging
GO:1900180 regulation of protein localization to nucleus
GO:1903243 negative regulation of cardiac muscle hypertrophy in response to stress
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway

Cellular Component:
GO:0005634 nucleus
GO:0005635 nuclear envelope
GO:0005638 lamin filament
GO:0005652 nuclear lamina
GO:0005654 nucleoplasm
GO:0005829 cytosol
GO:0005882 intermediate filament
GO:0016607 nuclear speck
GO:0031965 nuclear membrane
GO:0048471 perinuclear region of cytoplasm


-  Descriptions from all associated GenBank mRNAs
  AK056143 - Homo sapiens cDNA FLJ31581 fis, clone NT2RI2002091, highly similar to LAMIN C.
LF206164 - JP 2014500723-A/13667: Polycomb-Associated Non-Coding RNAs.
X03445 - Human mRNA for nuclear envelope protein lamin C precursor.
X03444 - Human mRNA for nuclear envelope protein lamin A precursor.
AK122732 - Homo sapiens cDNA FLJ16247 fis, clone HCHON2003659, highly similar to LAMIN A.
AK026584 - Homo sapiens cDNA: FLJ22931 fis, clone KAT07501, highly similar to HSLAMAR Human mRNA for nuclear envelope protein lamin A precursor.
AY357727 - Homo sapiens progerin mRNA, complete cds.
BC014507 - Homo sapiens lamin A/C, mRNA (cDNA clone MGC:23638 IMAGE:4863480), complete cds.
BC033088 - Homo sapiens lamin A/C, mRNA (cDNA clone MGC:45654 IMAGE:3623265), complete cds.
BC000511 - Homo sapiens lamin A/C, mRNA (cDNA clone MGC:8539 IMAGE:2822703), complete cds.
BC003162 - Homo sapiens lamin A/C, mRNA (cDNA clone MGC:4219 IMAGE:2958052), complete cds.
AK130179 - Homo sapiens cDNA FLJ26669 fis, clone MPG03096, highly similar to LAMIN A.
M13451 - Human lamin C mRNA, complete cds.
AY528714 - Homo sapiens rhabdomyosarcoma antigen MU-RMS-40.12 mRNA, complete cds, alternatively spliced.
AB527090 - Synthetic construct DNA, clone: pF1KB4020, Homo sapiens LMNA gene for lamin A/C, without stop codon, in Flexi system.
EU831836 - Synthetic construct Homo sapiens clone HAIB:100066865; DKFZo004B0222 lamin A/C protein (LMNA) gene, encodes complete protein.
EU831758 - Synthetic construct Homo sapiens clone HAIB:100066787; DKFZo008B0221 lamin A/C protein (LMNA) gene, encodes complete protein.
EU832261 - Synthetic construct Homo sapiens clone HAIB:100067290; DKFZo004G1026 lamin A/C protein (LMNA) gene, encodes complete protein.
EU832167 - Synthetic construct Homo sapiens clone HAIB:100067196; DKFZo008G1025 lamin A/C protein (LMNA) gene, encodes complete protein.
KJ891551 - Synthetic construct Homo sapiens clone ccsbBroadEn_00945 LMNA gene, encodes complete protein.
KR709897 - Synthetic construct Homo sapiens clone CCSBHm_00007214 LMNA (LMNA) mRNA, encodes complete protein.
KR709898 - Synthetic construct Homo sapiens clone CCSBHm_00007240 LMNA (LMNA) mRNA, encodes complete protein.
KR709899 - Synthetic construct Homo sapiens clone CCSBHm_00007292 LMNA (LMNA) mRNA, encodes complete protein.
KJ891552 - Synthetic construct Homo sapiens clone ccsbBroadEn_00946 LMNA gene, encodes complete protein.
AY847595 - Homo sapiens lamin A/C transcript variant 1 (LMNA) mRNA, complete cds, alternatively spliced.
AY847596 - Homo sapiens lamin A/C transcript variant 1 (LMNA) mRNA, complete cds, alternatively spliced.
AY847597 - Homo sapiens lamin A/C transcript variant 1 (LMNA) mRNA, complete cds, alternatively spliced.
GQ891309 - Homo sapiens clone HEL-S-32a epididymis secretory sperm binding protein mRNA, complete cds.
GQ891406 - Homo sapiens clone HEL-S-124 epididymis secretory sperm binding protein mRNA, complete cds.
GQ891408 - Homo sapiens clone HEL-S-126 epididymis secretory sperm binding protein mRNA, complete cds.
AK057997 - Homo sapiens cDNA FLJ25268 fis, clone STM05518, highly similar to LAMIN A.
AK295390 - Homo sapiens cDNA FLJ56081 complete cds, highly similar to Lamin-A/C.
AK097801 - Homo sapiens cDNA FLJ40482 fis, clone TESTI2043656, highly similar to LAMIN C.
AK056191 - Homo sapiens cDNA FLJ31629 fis, clone NT2RI2003360, highly similar to LAMIN A.
M13452 - Human lamin A mRNA, 3'end.
AK098128 - Homo sapiens cDNA FLJ40809 fis, clone TRACH2009661, highly similar to LAMIN A.
AK309539 - Homo sapiens cDNA, FLJ99580.
AK294217 - Homo sapiens cDNA FLJ55771 complete cds, highly similar to Lamin-A/C.
BC018863 - Homo sapiens lamin A/C, mRNA (cDNA clone IMAGE:3141665).
AF381029 - Homo sapiens lamin Adel10 mRNA, partial cds, alternatively spliced.
MA441741 - JP 2018138019-A/13667: Polycomb-Associated Non-Coding RNAs.
LF352110 - JP 2014500723-A/159613: Polycomb-Associated Non-Coding RNAs.
JD320837 - Sequence 301861 from Patent EP1572962.
JD139108 - Sequence 120132 from Patent EP1572962.
LF352109 - JP 2014500723-A/159612: Polycomb-Associated Non-Coding RNAs.
JD478019 - Sequence 459043 from Patent EP1572962.
CU678414 - Synthetic construct Homo sapiens gateway clone IMAGE:100020393 5' read LMNA mRNA.
CU677029 - Synthetic construct Homo sapiens gateway clone IMAGE:100023035 5' read LMNA mRNA.
LF352108 - JP 2014500723-A/159611: Polycomb-Associated Non-Coding RNAs.
LF352107 - JP 2014500723-A/159610: Polycomb-Associated Non-Coding RNAs.
LF352104 - JP 2014500723-A/159607: Polycomb-Associated Non-Coding RNAs.
LF352103 - JP 2014500723-A/159606: Polycomb-Associated Non-Coding RNAs.
DJ444898 - Combinatorial Methods and Compositions for Treatment of Melanoma.
CS027054 - Sequence 5 from Patent WO2005014837.
LF352102 - JP 2014500723-A/159605: Polycomb-Associated Non-Coding RNAs.
LF352101 - JP 2014500723-A/159604: Polycomb-Associated Non-Coding RNAs.
LF352100 - JP 2014500723-A/159603: Polycomb-Associated Non-Coding RNAs.
LF352099 - JP 2014500723-A/159602: Polycomb-Associated Non-Coding RNAs.
LF352098 - JP 2014500723-A/159601: Polycomb-Associated Non-Coding RNAs.
LF352096 - JP 2014500723-A/159599: Polycomb-Associated Non-Coding RNAs.
MA587687 - JP 2018138019-A/159613: Polycomb-Associated Non-Coding RNAs.
MA587686 - JP 2018138019-A/159612: Polycomb-Associated Non-Coding RNAs.
MA587685 - JP 2018138019-A/159611: Polycomb-Associated Non-Coding RNAs.
MA587684 - JP 2018138019-A/159610: Polycomb-Associated Non-Coding RNAs.
MA587681 - JP 2018138019-A/159607: Polycomb-Associated Non-Coding RNAs.
MA587680 - JP 2018138019-A/159606: Polycomb-Associated Non-Coding RNAs.
MA587679 - JP 2018138019-A/159605: Polycomb-Associated Non-Coding RNAs.
MA587678 - JP 2018138019-A/159604: Polycomb-Associated Non-Coding RNAs.
MA587677 - JP 2018138019-A/159603: Polycomb-Associated Non-Coding RNAs.
MA587676 - JP 2018138019-A/159602: Polycomb-Associated Non-Coding RNAs.
MA587675 - JP 2018138019-A/159601: Polycomb-Associated Non-Coding RNAs.
MA587673 - JP 2018138019-A/159599: Polycomb-Associated Non-Coding RNAs.
LF352095 - JP 2014500723-A/159598: Polycomb-Associated Non-Coding RNAs.
LF352094 - JP 2014500723-A/159597: Polycomb-Associated Non-Coding RNAs.
JD074993 - Sequence 56017 from Patent EP1572962.
LF352093 - JP 2014500723-A/159596: Polycomb-Associated Non-Coding RNAs.
JD481784 - Sequence 462808 from Patent EP1572962.
JD289541 - Sequence 270565 from Patent EP1572962.
JD411041 - Sequence 392065 from Patent EP1572962.
JD202775 - Sequence 183799 from Patent EP1572962.
JD053445 - Sequence 34469 from Patent EP1572962.
JD258627 - Sequence 239651 from Patent EP1572962.
JD341491 - Sequence 322515 from Patent EP1572962.
JD546412 - Sequence 527436 from Patent EP1572962.
JD398558 - Sequence 379582 from Patent EP1572962.
JD142086 - Sequence 123110 from Patent EP1572962.
JD475115 - Sequence 456139 from Patent EP1572962.
JD213406 - Sequence 194430 from Patent EP1572962.
JD229189 - Sequence 210213 from Patent EP1572962.
LF352092 - JP 2014500723-A/159595: Polycomb-Associated Non-Coding RNAs.
JD333132 - Sequence 314156 from Patent EP1572962.
JD498342 - Sequence 479366 from Patent EP1572962.
JD436019 - Sequence 417043 from Patent EP1572962.
JD042440 - Sequence 23464 from Patent EP1572962.
JD167931 - Sequence 148955 from Patent EP1572962.
LF352091 - JP 2014500723-A/159594: Polycomb-Associated Non-Coding RNAs.
JD247614 - Sequence 228638 from Patent EP1572962.
JD222395 - Sequence 203419 from Patent EP1572962.
JD481016 - Sequence 462040 from Patent EP1572962.
JD471485 - Sequence 452509 from Patent EP1572962.
JD320708 - Sequence 301732 from Patent EP1572962.
JD116150 - Sequence 97174 from Patent EP1572962.
JD099290 - Sequence 80314 from Patent EP1572962.
JD473221 - Sequence 454245 from Patent EP1572962.
JD155690 - Sequence 136714 from Patent EP1572962.
MA587672 - JP 2018138019-A/159598: Polycomb-Associated Non-Coding RNAs.
MA587671 - JP 2018138019-A/159597: Polycomb-Associated Non-Coding RNAs.
MA587670 - JP 2018138019-A/159596: Polycomb-Associated Non-Coding RNAs.
MA587669 - JP 2018138019-A/159595: Polycomb-Associated Non-Coding RNAs.
MA587668 - JP 2018138019-A/159594: Polycomb-Associated Non-Coding RNAs.

-  Biochemical and Signaling Pathways
  BioCarta from NCI Cancer Genome Anatomy Project
h_HivnefPathway - HIV-I Nef: negative effector of Fas and TNF
h_fasPathway - FAS signaling pathway ( CD95 )
h_caspasePathway - Caspase Cascade in Apoptosis
h_deathPathway - Induction of apoptosis through DR3 and DR4/5 Death Receptors
h_tnfr1Pathway - TNFR1 Signaling Pathway

Reactome (by CSHL, EBI, and GO)

Protein P02545 (Reactome details) participates in the following event(s):

R-HSA-264865 Caspase-mediated cleavage of Lamin A
R-HSA-8868344 CDK5:p25 phosphorylates lamin A
R-HSA-2995376 BANF1 binds chromatin, EMD/TMPO/LEMD3/LEMD2 and lamins
R-HSA-5244669 CDK1 phosphorylates lamins and facilitates depolymerization of lamin filaments
R-HSA-352238 Breakdown of the nuclear lamina
R-HSA-8862803 Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-111465 Apoptotic cleavage of cellular proteins
R-HSA-8863678 Neurodegenerative Diseases
R-HSA-75153 Apoptotic execution phase
R-HSA-1643685 Disease
R-HSA-2995383 Initiation of Nuclear Envelope Reformation
R-HSA-4419969 Depolymerisation of the Nuclear Lamina
R-HSA-109581 Apoptosis
R-HSA-2995410 Nuclear Envelope Reassembly
R-HSA-2980766 Nuclear Envelope Breakdown
R-HSA-5357801 Programmed Cell Death
R-HSA-68882 Mitotic Anaphase
R-HSA-68875 Mitotic Prophase
R-HSA-2555396 Mitotic Metaphase and Anaphase
R-HSA-68886 M Phase
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-1640170 Cell Cycle
R-HSA-2995376 BANF1 binds chromatin, EMD/TMPO/LEMD3/LEMD2 and lamins
R-HSA-5244669 CDK1 phosphorylates lamins and facilitates depolymerization of lamin filaments
R-HSA-1221632 Meiotic synapsis
R-HSA-1500620 Meiosis
R-HSA-1474165 Reproduction
R-HSA-1640170 Cell Cycle
R-HSA-2995383 Initiation of Nuclear Envelope Reformation
R-HSA-4419969 Depolymerisation of the Nuclear Lamina
R-HSA-2995410 Nuclear Envelope Reassembly
R-HSA-2980766 Nuclear Envelope Breakdown
R-HSA-68882 Mitotic Anaphase
R-HSA-68875 Mitotic Prophase
R-HSA-2555396 Mitotic Metaphase and Anaphase
R-HSA-68886 M Phase
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-6802927 BRAF and RAF fusion mutant dimers are phosphorylated
R-HSA-6802934 p-BRAF and RAF fusion dimers bind MAP2Ks and MAPKs
R-HSA-6802932 Dissociation of BRAF/RAF fusion complex
R-HSA-6802933 p-BRAF and RAF fusion dimers phosphorylate MAP2Ks
R-HSA-6802935 MAPKs are phosphorylated downstream of BRAF and RAF fusion dimers
R-HSA-381038 XBP1(S) activates chaperone genes
R-HSA-381070 IRE1alpha activates chaperones
R-HSA-381119 Unfolded Protein Response (UPR)
R-HSA-6802952 Signaling by BRAF and RAF fusions
R-HSA-392499 Metabolism of proteins
R-HSA-6802957 Oncogenic MAPK signaling
R-HSA-5663202 Diseases of signal transduction
R-HSA-1643685 Disease

-  Other Names for This Gene
  Alternate Gene Symbols: B4DI32, D3DVB0, D6RAQ3, E7EUI9, ENST00000368300.1, ENST00000368300.2, ENST00000368300.3, ENST00000368300.4, ENST00000368300.5, ENST00000368300.6, ENST00000368300.7, ENST00000368300.8, LMN1, LMNA_HUMAN, NM_170707, P02545, P02546, Q5I6Y4, Q5I6Y6, Q5TCJ2, Q5TCJ3, Q6UYC3, Q969I8, Q96JA2, uc318gqo.1, uc318gqo.2
UCSC ID: ENST00000368300.9_4
RefSeq Accession: NM_170707.4
Protein: P02545 (aka LMNA_HUMAN)

-  GeneReviews for This Gene
  GeneReviews article(s) related to gene LMNA:
cmt (Charcot-Marie-Tooth Hereditary Neuropathy Overview)
dcm-lmna (LMNA-Related Dilated Cardiomyopathy)
dcm-ov (Dilated Cardiomyopathy Overview)
edmd (Emery-Dreifuss Muscular Dystrophy)
hgps (Hutchinson-Gilford Progeria Syndrome)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.